Ovarian cancer in patients whose disease has progressed or recurred after platinum-based chemotherapy. AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. In combination w/ bortezomib for patients w/ multiple myeloma who have not previously received bortezomib & have received at least 1 prior therapy.
IV Administer 1st dose at initial rate of 1 mg/min. Increase the infusion rate to complete over 1 hr if no infusion-related adverse reactions are observed. Ovarian cancer 50 mg/m2 IV over 60 min every 28 days until disease progression or unacceptable toxicity. AIDS-related Kaposi's sarcoma 20 mg/m2 IV over 60 min every 21 days until disease progression or unacceptable toxicity. Multiple myeloma 30 mg/m2 IV over 60 min on day 4 of each 21-day cycle for 8 cycles or until disease progression or unacceptable toxicity. Administer doxorubicin inj after bortezomib on day 4 of each cycle.
Discontinue use if patient experiences serious or life-threatening infusion-related reactions. Risk of cardiomyopathy; patients who have received other anthracyclines or w/ prior mediastinal irradiation. Assess left ventricular cardiac function (eg, MUGA or echocardiogram) prior to initiation, during, & after treatment. Delay liposome inj for the 1st episode of grade ≥2 hand-foot syndrome (HFS). Discontinue treatment if HFS is severe & debilitating. Secondary oral cancer in long-term (>1 yr) exposure. Regularly examine for presence of oral ulceration or any oral discomfort that may be indicative of secondary oral cancer. Avoid use during 1st trimester of pregnancy. Discontinue breastfeeding during treatment. Use effective contraception during & for 6 mth following discontinuation of therapy in women of child-bearing potential or male partner. May cause infertility in female or male of reproductive potential.
Sign Out
